Panbela Therapeutics, Inc.

About Panbela Therapeutics, Inc.

Panbela Therapeutics is focused on developing disruptive therapeutics for patients with urgent unmet medical needs, particularly in oncology and orphan diseases. Their mission involves utilizing pharmacotherapies to normalize disease-associated polyamines through complementary approaches.

Products & Services

Polyamine Metabolic Inhibitor (PMI):A multi-targeted approach to reset dysregulated biology by reducing or normalizing increased disease-associated polyamines, targeting high unmet medical needs in oncology and orphan diseases.

Clinical Trials:Trials ranging from pre-clinical to Phase III, focusing on orphan oncology areas such as pancreatic cancer (ASPIRE trial) and familial adenomatous polyposis (FAP), with late-stage programs and global outreach.

Specialties

Oncology Orphan Diseases Polyamine Metabolic Inhibition Pancreatic Cancer Familial Adenomatous Polyposis (FAP) Non-Small Cell Lung Cancer

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 9000000 MR: - FA: Approximately $9.0 million FAN: 9000000	D: 2024-02-01 FD: 2024-02-01	1 investors
2	RT: Public Offering T: - FT: Public Offering	A: 9000000 MR: - FA: approximately $9.0 million FAN: 9000000	D: 2024-01-29 FD: 2024-01-29	1 investors
3	RT: Private Placement T: - FT: Private Placement	A: 2000000 MR: - FA: 2.0 Million FAN: 2000000	D: 2023-12-21 FD: 2023-12-21	1 investors
4	RT: Private Placement T: - FT: Private Placement	A: 1900000 MR: - FA: approximately $1.9 million FAN: 1900000	D: 2023-11-03 FD: 2023-11-03	-
5	RT: Public Offering T: - FT: Public Offering	A: 8500000 MR: - FA: approximately $8.5 million FAN: 8500000	D: 2023-06-21 FD: 2023-06-21	1 investors
6	RT: Public Offering T: - FT: Public Offering	A: 8500000 MR: - FA: approximately $8.5 million FAN: 8500000	D: 2023-06-16 FD: 2023-06-16	1 investors
7	RT: Public Offering T: - FT: Public Offering	A: 15000000 MR: - FA: approximately $15 million FAN: 15000000	D: 2023-01-26 FD: 2023-01-26	2 investors

Public Offering Latest

2024-02-01

$9.0M

1 investor (Pro only)

Public Offering 2024-01-29

$9.0M

Private Placement 2023-12-21

$2.0M

View 6 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Michael T. Cullen

Executive Chairman

J

Jennifer K Simpson

President and Chief Executive Officer

A

Art Fratamico

Chief Business Officer

D

Dan Donovan

Director and Chief Business Officer

J

Jeff Mathiesen

Director

J

Jeffrey Jacob

Director

View 11 more team members with Pro

Unlock Full Team Directory

Recent News